



Driscoll Health Plan

News and Updates



Date:

May 12
2025

Contact Information

For questions or additional assistance, contact:

Provider Relations
956-632-8308

To enter authorization requests and upload clinical via the Provider Portal, visit driscollhealthplan.com/providers

To verify authorization requirements via the Authorization Requirement Portal, visit driscollhealthplan.com/priorauthcheck

To submit authorization requests or clinical to the UM Dept. via fax, send to 1-866-741-5650

Attention: Authorization Requirement Updates

Effective 06/01/2025, DHP **will not** require prior authorization for the following procedure codes within the benefit limit:

Pharmacy Services

- C9302, zanidatamab-hrii, treatment of biliary tract cancer in members 18 years or older with diagnosis C22.1, C23, C24.0, C24.8, or C24.9.
- C9303, zolbetuximab-clzb, used in combination with chemotherapy to treat advanced, unresectable, or metastatic gastric or gastroesophageal junction adenocarcinoma in members 18 years or older with diagnosis C15.5, C15.8, C15.9, C16.0-C16.6, C16.8, or C16.9.
- C9304, marstacimab-hncq, treatment of Hemophilia A or B in members 12 years of age or older
- J0281, aminocaproic acid, managing and treating acute bleeding disorders resulting from elevated fibrinolytic activity.
- J1190, dexrazoxane hydrochloride, chemo-protective agent to reduce the risk of cardiotoxicity during chemotherapy treatments
- J1271, doxycycline hyclate, antibiotic for treatment of malaria, improve tooth attachment and reduce gum pockets in people who have a dental procedure.
- J1308, famotidine, reduce stomach acid.
- J1808, folic acid, chemotherapy toxicities.
- J1938, furosemide, treatment of fluid retention (edema) and swelling.
- J2290, nafcillin sodium, a narrow-spectrum β -lactam antibiotic.
- J2351, ocrelizumab, treatment of multiple sclerosis in members 18 years or older
- J2468, palonosetron hydrochloride (posfrea), prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy.
- J2472, pantoprazole sodium, treatment of erosive esophagitis caused by gastroesophageal reflux disease.
- J2804, rifampin, treatment of tuberculosis and meningitis bacterium in the nose or throat.
- J2865, administration of the combined antibiotic, sulfamethoxazole and trimethoprim, treatment of bacterial infections.
- J9024, atezolizumab, treatment of urothelial carcinoma, non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma and alveolar soft part sarcoma in members 18 years or older.
- J9054, Bortezomib (Boruzu), treatment of multiple myeloma and mantle cell lymphoma in members 18 years and older.

Wound Care

- 11000, debridement of extensive eczematous or infected skin

General Surgery Services

- 49186, excise or destroy one or more tumors or cysts in the patient's abdomen. The sum of the maximum length of the tumors or cysts is 5 cm or less.
- 49187, excise or destroy one or more tumors or cysts in the patient's abdomen. The sum of the maximum length of the tumors or cysts is 5.1 to 10 cm.
- 49188, excise or destroy one or more tumors or cysts in the patient's abdomen. The sum of the maximum length of the tumors or cysts is 10.1 to 20 cm.
- 49189, excise or destroy one or more tumors or cysts in the patient's abdomen. The sum of the maximum length of the tumors or cysts is 20.1 to 30 cm.
- 49190, excise or destroy one or more tumors or cysts in the patient's abdomen. The sum of the maximum length of the tumors or cysts is greater than 30 cm.

* To access the DHP provider portal , visit driscollhealthplan.com